Focused On-demand Library for Secreted frizzled-related protein 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q92765

UPID:

SFRP3_HUMAN

Alternative names:

Frezzled; Fritz; Frizzled-related protein 1; FrzB-1

Alternative UPACC:

Q92765; O00181; Q99686

Background:

Secreted frizzled-related protein 3 (SFRP3), also known by alternative names such as Frezzled, Fritz, and Frizzled-related protein 1, plays a pivotal role in Wnt signaling modulation. It directly interacts with Wnts, influencing cell growth and differentiation in specific cell types. SFRP3 is crucial in limb skeletogenesis and acts as an antagonist of Wnt8 signaling, guiding chondrocyte maturation and long bone development.

Therapeutic significance:

SFRP3's involvement in osteoarthritis 1, a degenerative joint disease, highlights its potential as a therapeutic target. Disease susceptibility linked to gene variants affecting SFRP3 underscores the importance of understanding its function for developing treatments aimed at alleviating pain, stiffness, and disability associated with osteoarthritis.